EA
CLDX icon

Emerald Acquisition’s Celldex Therapeutics CLDX Stock Holding History

Emerald Acquisition’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$43K Sell
712
-6,476
-90% -$403K ﹤0.01% 2896
2016
Q2 		$473K Buy
+7,188
New +$456K ﹤0.01% 2488

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Emerald Acquisition's CLDX Position: Q3 2016 in Review

Emerald Acquisition reduced its Celldex Therapeutics (CLDX) stake by 90% in Q3 2016, selling an estimated $403K and leaving 712 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

Emerald Acquisition first reported a position in CLDX in Q2 2016 and has held it in 2 quarters since. The position peaked at $473K in Q2 2016. 138 funds tracked by Wall St. Rank hold CLDX as of Q3 2016.

  • Emerald Acquisition held 712 shares of Celldex Therapeutics worth $43K as of Q3 2016.
  • Emerald Acquisition sold 6,476 Celldex Therapeutics shares in Q3 2016, an estimated $403K.
  • Celldex Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2896 holding.
  • Emerald Acquisition first reported a position in Celldex Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Celldex Therapeutics position peaked at $473K in Q2 2016.
  • 138 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.